Alumis Inc. $ALMS Shares Purchased by BML Capital Management LLC

BML Capital Management LLC grew its holdings in Alumis Inc. (NASDAQ:ALMS) by 2,339.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,210,415 shares of the company’s stock after acquiring an additional 1,160,788 shares during the quarter. Alumis accounts for about 2.7% of BML Capital Management LLC’s investment portfolio, making the stock its 10th largest holding. BML Capital Management LLC owned about 2.22% of Alumis worth $3,631,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ALMS. Corebridge Financial Inc. lifted its stake in Alumis by 53.0% in the first quarter. Corebridge Financial Inc. now owns 10,658 shares of the company’s stock valued at $65,000 after buying an additional 3,693 shares in the last quarter. Credit Industriel ET Commercial increased its position in shares of Alumis by 178.8% during the second quarter. Credit Industriel ET Commercial now owns 387,002 shares of the company’s stock worth $1,161,000 after acquiring an additional 248,202 shares in the last quarter. Blair William & Co. IL acquired a new stake in shares of Alumis during the second quarter worth $200,000. Tybourne Capital Management HK Ltd. acquired a new stake in shares of Alumis during the second quarter worth $4,198,000. Finally, Towerview LLC lifted its position in Alumis by 15.1% in the 2nd quarter. Towerview LLC now owns 495,000 shares of the company’s stock valued at $1,485,000 after acquiring an additional 65,000 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ALMS shares. Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Alumis in a research report on Thursday, August 14th. Wells Fargo & Company assumed coverage on Alumis in a report on Friday, July 25th. They set an “overweight” rating and a $17.00 price objective for the company. Morgan Stanley dropped their target price on Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research report on Thursday. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alumis currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.20.

Alumis Stock Performance

ALMS opened at $5.52 on Friday. The business’s 50-day simple moving average is $4.49 and its 200 day simple moving average is $4.19. Alumis Inc. has a 52-week low of $2.76 and a 52-week high of $10.64. The firm has a market capitalization of $574.43 million, a PE ratio of -1.17 and a beta of -1.33.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. On average, research analysts forecast that Alumis Inc. will post -8.51 earnings per share for the current year.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.